Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

92.97+0.18 (+0.19%)

At close: 4:00PM EDT

93.00 +0.03 (0.03%)
After hours: 6:48PM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Triple Moving Average Crossover

View all chart patterns

Performance Outlook

Previous Close	92.79
Open	93.62
Bid	92.96 x 800
Ask	95.57 x 1000
Day's Range	91.80 - 94.11
52 Week Range	86.02 - 136.26
Volume	815,798
Avg. Volume	1,239,031

Market Cap	8.789B
Beta (5Y Monthly)	0.79
PE Ratio (TTM)	22.35
EPS (TTM)	4.16
Earnings Date	May 04, 2021 - May 10, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	Dec 29, 1995
1y Target Est	127.38

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Near Fair Value

-6% Est. Return

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

PR Newswire
Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy of Neurology's (AAN) 73rd Annual Meeting being held virtually from April 17–22, 2021.
- Harmony Biosciences To Present WAKIX® (Pitolisant) Data At The 2021 AAN Annual Meeting
  PR Newswire
- Neurelis Announces Two Poster Presentations for the Annual Meeting of the Academy of Managed Care Pharmacy
  PR Newswire
Zacks
Strength Seen in Neurocrine (NBIX): Can Its 11.1% Jump Turn into More Strength?
Neurocrine (NBIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PR Newswire
Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Apr. 1, 2021. Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the conference.